UBS Raises Bayer to Buy, Lifts 12-Month Target to €52 as Glyphosate Settlement Advances
UBS upgraded Bayer from neutral to buy and increased its 12-month price target to €52 from €48 after a U.S. court granted preliminary approval to the company’s $7.25 billion proposed glyphosate settlement. The bank mapped multiple settlement and litigation scenarios that produce valuations between €35 and €60 per share, and updated operational and …